Clinical Trials on Neuroendocrine Carcinoma of the Bladder

Total 11218 results

Peking University

Recruiting

Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma

Neuroendocrine Carcinoma of the Bladder

China
RenJi Hospital

Recruiting

Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma (RJBLC-NEBC001)

Bladder Cancer | Neuroendocrine Carcinoma of the Bladder

China
Memorial Sloan Kettering Cancer Center
AstraZeneca

Completed

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Adenocarcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder | Metastatic Bladder Cancer | Non-Transitional Cell Carcinoma of the Urothelial Tract | Small Cell of the Bladder

United States
National Cancer Institute (NCI)

Completed

Oblimersen in Treating Patients With Merkel Cell Carcinoma

Recurrent Neuroendocrine Carcinoma of the Skin | Stage III Neuroendocrine Carcinoma of the Skin | Stage IV Neuroendocrine Carcinoma of the Skin | Stage II Neuroendocrine Carcinoma of the Skin | Stage I Neuroendocrine Carcinoma of the Skin

United States
National Cancer Institute (NCI)

Completed

S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Recurrent Neuroendocrine Carcinoma of the Skin | Stage III Neuroendocrine Carcinoma of the Skin | Stage II Neuroendocrine Carcinoma of the Skin

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer

Urothelial Carcinoma of the Bladder

United States
National Cancer Institute (NCI)

Not yet recruiting

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

Squamous Cell Carcinoma of the Penis | Renal Medullary Carcinoma | Squamous Cell Carcinoma of the Bladder | Small Cell Carcinoma of the Bladder | Small Cell Carcinoma of the Urinary Tract | Squamous Cell Carcinoma of the Urinary Tract | Primary Adenocarcinoma of the Bladder | Primary Adenocarcinoma...

United States
National Cancer Institute (NCI)

Recruiting

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Small Cell Carcinoma of the Bladder | High Grade Neuroendocrine Tumors of the Urinary Tract

United States
National Cancer Institute (NCI)

Completed

Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder

United States
National Cancer Institute (NCI)

Terminated

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional... and other conditions

United States
National Cancer Institute (NCI)

Completed

VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Adenocarcinoma of the Bladder | Distal... and other conditions

United States
Noah Hahn, M.D.
Pfizer; Hoosier Cancer Research Network

Terminated

Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC

Transitional Cell Carcinoma of the Bladder

United States, United Kingdom
Hoosier Cancer Research Network
Bristol-Myers Squibb

Completed

Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder

Transitional Cell Carcinoma of the Bladder

United States
Emory University

Terminated

Adjuvant Radiation for High Risk Bladder Cancer

Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Genentech, Inc.

Recruiting

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Bladder Cancer | Small Cell Neuroendocrine Carcinoma of Bladder | Urothelial Carcinoma Bladder

United States
Oncolytics Biotech

Withdrawn

Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

Muscle-invasive Transitional Cell Carcinoma of the Bladder
Erasmus Medical Center
Merck Sharp & Dohme LLC

Active, not recruiting

Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab (RESPONDER)

Biomarkers | Transitional Cell Carcinoma of the Bladder

Netherlands
Medical Enterprises Ltd.

Terminated

Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors. (RITE-USA)

Urinary Bladder Cancer | Bladder Cancer | Malignant Tumor of Urinary Bladder | Bladder Neoplasm | Cancer of Bladder | Carcinoma in Situ of Bladder | Bladder Tumors | Cancer of the Bladder | Neoplasms, Bladder | Papillary Carcinoma of Bladder (Diagnosis) | BCG-Unresponsive Bladder Cancer

United States
Perspective Therapeutics

Recruiting

Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (212-Pb-VMT)

Neuroendocrine Tumors | Pheochromocytoma | Carcinoid Tumor | Paraganglioma | Neuroendocrine Tumor of the Lung | Neuroendocrine Carcinoma Metastatic | Neuroendocrine Tumor of Pancreas | Neuroendocrine Tumor Carcinoid | Carcinoid Tumor of GI System

United States
National Cancer Institute (NCI)

Terminated

Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Transitional Cell Carcinoma of the Bladder | Localized Transitional Cell Cancer of the...

United States
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Merkel Cell Carcinoma | Neuroendocrine Carcinoma of the Skin | Trabecular Carcinoma of the Skin

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional...

Canada
BioNTech US Inc.
Bristol-Myers Squibb

Completed

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Melanoma | Carcinoma, Non-Small-Cell Lung | Lung Cancer | Urinary Bladder Cancer | Skin Cancer | Transitional Cell Carcinoma of the Bladder | Malignant Melanoma | Bladder Tumors

United States
University of California, Davis
Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

Recurrent Bladder Carcinoma | Stage III Urethral Cancer | Stage IV Urethral Cancer | Urethral Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma | Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter | Stage III Bladder Urothelial Carcinoma | Recurrent Urothelial Carcinoma of... and other conditions

United States
Five Prime Therapeutics, Inc.

Completed

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Gastric Cancer | Advanced Solid Tumors | Transitional Cell Carcinoma of the Bladder

Korea, Republic of, United States, Taiwan
Fox Chase Cancer Center

Active, not recruiting

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Urothelial Carcinoma of the Bladder

United States
Novartis Pharmaceuticals

Completed

3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial (LUNA)

Neuroendocrine Carcinoma of the Lung and Thymus

Italy, United Kingdom, Netherlands, Spain, Germany, France, Greece, Denmark, Sweden
Oncology Center of Biochemical Education And Research

Completed

Atezolizumab in Large Cell Neuroendocrine Carcinoma (LANCE)

Large Cell Neuroendocrine Carcinoma of the Lung

Greece
Ochsner Health System
Merck Sharp & Dohme LLC

Withdrawn

Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma

Neuroendocrine Carcinoma | Large Cell Neuroendocrine Carcinoma of the Lung | High Grade Neuroendocrine Carcinoma, Any Site

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts

Urothelial Carcinoma of the Bladder

United States
Claudia Guerrieri

Enrolling by invitation

Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer (SURE-02)

Muscle-invasive Urothelial Carcinoma of the Bladder

Italy
Fidia Farmaceutici s.p.a.

Completed

ONCOFID-P-B in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder.

Non-Invasive Papillary Carcinoma of Bladder

Spain, Germany, Italy
National Cancer Institute (NCI)

Completed

Arsenic Trioxide in Treating Patients With Urothelial Cancer

Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Transitional Cell Carcinoma of the Bladder | Ureter Cancer | Recurrent Urethral Cancer

United States
NanOlogy, LLC
US Biotest, Inc.

Completed

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Urologic Neoplasms | Urogenital Neoplasms | Urinary Bladder Cancer | Bladder Cancer | Urothelial Carcinoma | Urologic Cancer | Urinary Bladder Neoplasm | Cancer of the Bladder | Malignant Tumor of the Urinary Bladder

United States
Technische Universität Dresden
Roche Pharma AG

Recruiting

A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung (LCNEC-ALPINE)

Large Cell Neuroendocrine Carcinoma of the Lung

Germany
Guarionex J. Decastro
Sanofi

Active, not recruiting

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder (CGC)

Urothelial Carcinoma of the Urinary Bladder

United States
Fox Chase Cancer Center

Completed

Dose Dense MVAC for Muscle Invasive Bladder Cancer

Muscle Invasive Bladder Cancer | High Risk Urothelial Carcinoma of the Upper Urinary Tracts

United States
Travera Inc
xCures

Recruiting

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) (TraveraRTGx)

Melanoma | Carcinoma, Renal Cell | Carcinoma | Carcinoma, Non-Small-Cell Lung | Carcinoma, Hepatocellular | Carcinoma, Pancreatic | Pancreatic Cancer | Mesothelioma | Cholangiocarcinoma | Carcinoma, Neuroendocrine | Carcinoma, Small Cell | Pleural Effusion, Malignant | Carcinoma, Pancreatic Ductal | Carcinoma of the... and other conditions

United States
National Cancer Institute (NCI)

Completed

Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional... and other conditions

United States
University of Aarhus

Unknown

Evaluation Study of Ultrasound Bladder Scanner for Monitoring Bladder Function

Dysfunction of the Urinary Bladder

Denmark
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer

Neuroendocrine Carcinoma of the Skin

United States
National Cancer Institute (NCI)

Not yet recruiting

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

Adenocarcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder | Testicular Germ Cell Tumors

United States
Advanced Accelerator Applications

Completed

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1)

Carcinoid Tumor of the Small Bowel | Neuroendocrine Tumour

United States, United Kingdom, Italy, Belgium, France, Germany, Portugal, Spain
Acrotech Biopharma Inc.

Completed

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Carcinoma, Transitional Cell | Bladder Cancer | Bladder Neoplasm

Spain, France, Belgium, United States, Argentina, Croatia
National Cancer Institute (NCI)

Completed

Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Ureter Cancer | Recurrent Urethral... and other conditions

United States
Latin American Cooperative Oncology Group

Terminated

Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

Bladder Cancer | Urothelial Carcinoma

Brazil
National Cancer Institute (NCI)

Terminated

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent... and other conditions

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Urothelial Carcinoma | Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Bladder Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral... and other conditions

United States
National Cancer Institute (NCI)

Completed

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent Urethral Cancer | Urethral Cancer Associated With Invasive Bladder Cancer

United States, China, Korea, Republic of

Clinical Trials on Neuroendocrine Carcinoma of the Bladder

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations